home / stock / aclx / aclx news

ACLX News and Press, Arcellx Inc. From 07/12/22

Stock Information
Company Name: Arcellx Inc.
Stock Symbol: ACLX
Market: NASDAQ
Website: arcellx.com
Menu
ACLX ACLX Quote ACLX Short ACLX News ACLX Articles ACLX Message Board
Get ACLX Alerts

News, Short Squeeze, Breakout and More Instantly...
ACLX - Greenwich, Histogen top healthcare gainers; Can-Fite, Arcellx lead losers' pack

Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...
ACLX - ASCO Annual Meeting 2022: An Innovation Showcase In Cancer Treatment

At the ASCO meeting, BioNTech presented phase-1 clinical trial data for its mRNA-based vaccine for pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. AstraZeneca and Daiichi presented data for the Destiny-Breast04 trial, which tested Enhertu against chemother...

ACLX - Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares

Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares PR Newswire REDWOOD CITY, Calif. , June 21, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology com...

ACLX - Bone Biologics, Akero top healthcare gainers; AC Immune, Arcellx lead losers' pack

Gainers: Bone Biologics (BBLG) +13%. Akero Therapeutics AKRO +10%. Biotricity (BTCY) +9%. Jasper Therapeutics (JSPR) +7%. Burning Rock Biotech (BNR) +6%. Losers: AC Immune ACIU -17%. Arcellx ACLX -17%. SOPHiA GENETICS (SOPH) -16%. AirSculpt Te...
ACLX - MFGP, SRNE and OPEN among pre market losers

AC Immune (ACIU) -32%  as crenezumab fails in Alzheimer's study. Cango (CANG) -30%. Absci (ABSI) -14%. Hillstream BioPharma (HILS) -11%. Cepton (CPTN) -7%. Enservco Corporation (ENSV) -10%. Arcellx (ACLX) -10% on upsizing of follow-on public offering of 7M shares at $...

ACLX - Arcellx Announces Upsizing and Pricing of Follow-On Public Offering

Arcellx Announces Upsizing and Pricing of Follow-On Public Offering PR Newswire -- Public Offering of 7,000,000 Shares of Common Stock for Gross Proceeds of $112 Million -- REDWOOD City, Calif. , June 15, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ...

ACLX - Gelesis, Entrada top healthcare gainers; Outset Medical, Arcellx lead losers' pack

Gainers: Gelesis (GLS) +14%. Entrada Therapeutics (TRDA) +10%. Rhythm Pharmaceuticals (RYTM) +9%.  Vivos Therapeutics (VVOS) +7%. Genfit (GNFT) +6%. Losers: Outset Medical (OM) -31%. Arcellx (ACLX) -17%. Neptune Wellness Solutions NEPT -12%. H...
ACLX - ASCO 2022: Surprising News in Cancer Research

The American Society of Clinical Oncology (ASCO) held its annual meeting this week, and it's a must-show event for anybody pursuing cancer therapies. Our mini-roundtable has been digging into some of the presentations, and we found a few companies announcing nice surprises, among them, Ad...

ACLX - Bluejay, DBV top healthcare gainers; Precision, Blueprint among losers' pack

Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...

ACLX - Arcellx: Speculative Buy For Their 'Best-In-Class' CAR-T Cell Therapy

ACLX is a clinical-stage biotech that aims to develop potentially "safer, more effective, and more broadly accessible" CAR-T cell therapies for cancers and incurable diseases. On June 3, ACLX presented p1 data of their lead candidate, CART-ddBCMA, for relapsed or refractory multiple m...
Previous 10 Next 10